STUDY ON CHARACTERISTICS OF GENERALIZED ANXIETY DISORDER IN PATIENTS WITH MYASTHENIA GRAVIS AT MILITARY HOSPITAL 103

Dinh Son Nhu1, Thi Phuong Loan Tran1, , Ta Hai Ninh Duong1, Minh Anh Tran1, Thi Thu Ha Nguyen1, Ba Tung Nguyen2
1 Khoa Thần kinh, Bệnh viện Quân y 103, Học viện Quân y
2 Học viện Quân y

Main Article Content

Abstract

Objectives: To evaluate the characteristics of generalized anxiety disorder (GAD) and its association with certain clinical features in patients with myasthenia gravis (MG) at Military Hospital 103. Methods: A cross-sectional descriptive study was conducted on 83 MG patients treated at Military Hospital 103, from July 2024 to April 2025. Inclusion criteria were patients diagnosed with MG according to the 2022 Japanese Guidelines. Patients with a history of psychiatric disorders prior to MG onset or those receiving anti-anxiety medications at the time of assessment were excluded. GAD was diagnosed by psychiatrists according to the DSM-5 criteria, and its severity was assessed using the Zung Self-Rating Anxiety Scale. Results: The prevalence of GAD among MG patients was 36.14%, predominantly mild (33.73%), and 2.41% of cases was moderate. The most commonly reported symptom was fatigue. GAD was significantly associated with females and a history of myasthenic crisis. Conclusion: GAD is relatively common among patients with MG. Female gender and a history of myasthenic crisis were identified as significant factors associated with anxiety in patients with MG.

Article Details

References

1. Salari N, Fatahi B, Bartina Y, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: A systematic review and meta-analysis. J Transl Med. 2021; 19(1):516.
2. Nadali J, Ghavampour N, Beiranvand F, et al. Prevalence of depression and anxiety among myasthenia gravis (MG) patients: A systematic review and meta-analysis. Brain Behav. 2023; 13(1):e2840.
3. Phạm Kiều Anh Thơ, Nguyễn Thanh Bình. Đặc điểm lâm sàng và test kích thích thần kinh lặp lại ở bệnh nhân nhược cơ. Tạp chí Nghiên cứu Y học. 2021; 137(1):213-221.
4. Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: Clinical, immunological, and therapeutic advances. Acta Neurol Scand. 2005; 111(2):134-141.
5. Keesey JC. Does myasthenia gravis affect the brain? J Neurol Sci.1999; 170(2):77-89.
6. Magni G, Micaglio GF, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand. 1988; 77(4):443-445.
7. Ströhle A, Gensichen J, Domschke K. The diagnosis and treatment of anxiety disorders. Dtsch Arztebl Int. 2018; 155(37):611-620.
8. Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: Aetiology, diagnosis and treatment. CNS Drugs. 2007; 21(6):473-481.
9. Aysal F, Karamustafalioğlu O, Özçelik B, et al. The relationship of symptoms of anxiety and depression with disease severity and treatment modality in myasthenia gravis: A cross-sectional study. Noro Psikiyatr Ars. 2013; 50(4):295-300.
10. Freeman Carla, Lewis Ian, Heckmann Jeannine. Neuropsychiatric symptoms in patients with thymoma-associated and non-thymoma myasthenia gravis. South African Journal of Psychiatry. 2014; 20:50.